Diazoxide - Generic Drug Details
What are the generic sources for diazoxide and what is the scope of patent protection?
Diazoxide
is the generic ingredient in four branded drugs marketed by Teva Branded Pharm, Abraxis Pharm, Schering, E5 Pharma Inc, Novitium Pharma, and Soleno, and is included in seven NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Three suppliers are listed for this compound.
Summary for diazoxide
| US Patents: | 6 |
| Tradenames: | 4 |
| Applicants: | 6 |
| NDAs: | 7 |
| Drug Master File Entries: | 5 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 43 |
| Patent Applications: | 5,873 |
| Drug Prices: | Drug price trends for diazoxide |
| What excipients (inactive ingredients) are in diazoxide? | diazoxide excipients list |
| DailyMed Link: | diazoxide at DailyMed |
Recent Clinical Trials for diazoxide
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | PHASE1 |
| Columbia University | PHASE1 |
| University of Pisa | PHASE1 |
Medical Subject Heading (MeSH) Categories for diazoxide
Anatomical Therapeutic Chemical (ATC) Classes for diazoxide
US Patents and Regulatory Information for diazoxide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Soleno | VYKAT XR | diazoxide choline | TABLET, EXTENDED RELEASE;ORAL | 216665-003 | Mar 26, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Soleno | VYKAT XR | diazoxide choline | TABLET, EXTENDED RELEASE;ORAL | 216665-002 | Mar 26, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Soleno | VYKAT XR | diazoxide choline | TABLET, EXTENDED RELEASE;ORAL | 216665-001 | Mar 26, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Soleno | VYKAT XR | diazoxide choline | TABLET, EXTENDED RELEASE;ORAL | 216665-001 | Mar 26, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Soleno | VYKAT XR | diazoxide choline | TABLET, EXTENDED RELEASE;ORAL | 216665-001 | Mar 26, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Soleno | VYKAT XR | diazoxide choline | TABLET, EXTENDED RELEASE;ORAL | 216665-003 | Mar 26, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
